NOX — Noxopharm Balance Sheet
0.000.00%
Last trade - 00:00- AU$30.68m
- AU$31.61m
- AU$2.83m
Annual balance sheet for Noxopharm, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | R2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 26.8 | 14 | 3.01 | 2.32 | 1.55 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 5.8 | 5.21 | 6.08 | 2.4 | 2.95 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 33 | 20.8 | 9.16 | 4.77 | 4.58 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.484 | 0.222 | 0.007 | 0.006 | 0.004 |
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 47.9 | 26.6 | 10.1 | 6.78 | 4.58 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Current Liabilities | 6.81 | 2.28 | 0.962 | 1.25 | 3.87 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 7.08 | 2.48 | 1.06 | 1.29 | 3.89 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 40.8 | 24.1 | 9.07 | 5.5 | 0.69 |
| Total Liabilities & Shareholders' Equity | 47.9 | 26.6 | 10.1 | 6.78 | 4.58 |
| Total Common Shares Outstanding |